HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study
Objectives: Retrospective analysis of evolution of HIV tropism and association with disease progression in perinatal HIV-1 infection (PaHIV). Methodology: Eligible patients with PaHIV were grouped as slow, rapid or long-term non-progressors (LTNP). The V3 region of gp120 was sequenced from stored pl...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-07-01
|
Series: | Journal of Virus Eradication |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664020305057 |
id |
doaj-57cc5682a6444f479855d284077ae546 |
---|---|
record_format |
Article |
spelling |
doaj-57cc5682a6444f479855d284077ae5462021-05-04T07:23:49ZengElsevierJournal of Virus Eradication2055-66402015-07-0113173178HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP StudyC. Foster0S. Kaye1C. Smith2N.E. Mackie3Department of GU Medicine Imperial College Healthcare NHS Trus, LondonUK; Corresponding author: Caroline Foster, Department of GU Medicine Imperial College Healthcare NHS Trust, Praed Street, London, W2 1NY, UKDepartment of Retrovirology Imperial College London, UKResearch Department of Infection and Population Health University College London, UKDepartment of GU Medicine Imperial College Healthcare NHS Trus, LondonUKObjectives: Retrospective analysis of evolution of HIV tropism and association with disease progression in perinatal HIV-1 infection (PaHIV). Methodology: Eligible patients with PaHIV were grouped as slow, rapid or long-term non-progressors (LTNP). The V3 region of gp120 was sequenced from stored plasma samples and tropism determined by geno2pheno algorithm (FPR 5.75%). Logistic regression with generalised estimating equations assessed factors associated with R5 virus. Time to tropism change was assessed using standard survival methods. Results: At baseline (n=48) median age was 12 years (IQR 9.3–14.8), 52% were female, 79% were Black African, 96% were non-B subtypes and 81% (39/48) had R5-using virus. Median follow-up was 7.7 years (308.6 person-years), with a median of five (range 1–14) samples per subject (total 252). Analysing all samples, R5 virus was associated with higher current CD4 cell count (median 520 cells/mm3 R5 vs 202 for X4, P=0.0005), LTNP (35% vs 11%, P=0.05), non-Black ethnicity (74% vs 89%, P=0.05) and female gender (55% vs 28%, P=0.005). Twelve of 38 (31%) with R5 virus at baseline switched to X4/dual-using virus, with an estimated 5-year risk of switch of 24.4% (95% CI 9.7–39.2%) predicted by lower current CD4 cell count (unadjusted HR 0.62/50 cells higher, 95% CI 0.47–0.81, P=0.0006). Eleven of 19 (58%) with X4/dual-using virus subsequently had R5 virus at one or more time points. Conclusion: Maraviroc was a treatment option for 81% at 12 years, falling to 56% at 18 years, with lower CD4 cell count predictive of co-receptor switching. Paediatric studies of CCR5 antagonists should be expedited to ensure they are an early treatment option before tropism switching occurs.http://www.sciencedirect.com/science/article/pii/S2055664020305057co-receptor tropismperinatal HIVCCR5 antagonistchildrenadolescents |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
C. Foster S. Kaye C. Smith N.E. Mackie |
spellingShingle |
C. Foster S. Kaye C. Smith N.E. Mackie HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study Journal of Virus Eradication co-receptor tropism perinatal HIV CCR5 antagonist children adolescents |
author_facet |
C. Foster S. Kaye C. Smith N.E. Mackie |
author_sort |
C. Foster |
title |
HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study |
title_short |
HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study |
title_full |
HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study |
title_fullStr |
HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study |
title_full_unstemmed |
HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study |
title_sort |
hiv-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired hiv-1 infection. the hiccup study |
publisher |
Elsevier |
series |
Journal of Virus Eradication |
issn |
2055-6640 |
publishDate |
2015-07-01 |
description |
Objectives: Retrospective analysis of evolution of HIV tropism and association with disease progression in perinatal HIV-1 infection (PaHIV). Methodology: Eligible patients with PaHIV were grouped as slow, rapid or long-term non-progressors (LTNP). The V3 region of gp120 was sequenced from stored plasma samples and tropism determined by geno2pheno algorithm (FPR 5.75%). Logistic regression with generalised estimating equations assessed factors associated with R5 virus. Time to tropism change was assessed using standard survival methods. Results: At baseline (n=48) median age was 12 years (IQR 9.3–14.8), 52% were female, 79% were Black African, 96% were non-B subtypes and 81% (39/48) had R5-using virus. Median follow-up was 7.7 years (308.6 person-years), with a median of five (range 1–14) samples per subject (total 252). Analysing all samples, R5 virus was associated with higher current CD4 cell count (median 520 cells/mm3 R5 vs 202 for X4, P=0.0005), LTNP (35% vs 11%, P=0.05), non-Black ethnicity (74% vs 89%, P=0.05) and female gender (55% vs 28%, P=0.005). Twelve of 38 (31%) with R5 virus at baseline switched to X4/dual-using virus, with an estimated 5-year risk of switch of 24.4% (95% CI 9.7–39.2%) predicted by lower current CD4 cell count (unadjusted HR 0.62/50 cells higher, 95% CI 0.47–0.81, P=0.0006). Eleven of 19 (58%) with X4/dual-using virus subsequently had R5 virus at one or more time points. Conclusion: Maraviroc was a treatment option for 81% at 12 years, falling to 56% at 18 years, with lower CD4 cell count predictive of co-receptor switching. Paediatric studies of CCR5 antagonists should be expedited to ensure they are an early treatment option before tropism switching occurs. |
topic |
co-receptor tropism perinatal HIV CCR5 antagonist children adolescents |
url |
http://www.sciencedirect.com/science/article/pii/S2055664020305057 |
work_keys_str_mv |
AT cfoster hiv1coreceptortropismanddiseaseprogressioninchildrenandyoungadultswithperinatallyacquiredhiv1infectionthehiccupstudy AT skaye hiv1coreceptortropismanddiseaseprogressioninchildrenandyoungadultswithperinatallyacquiredhiv1infectionthehiccupstudy AT csmith hiv1coreceptortropismanddiseaseprogressioninchildrenandyoungadultswithperinatallyacquiredhiv1infectionthehiccupstudy AT nemackie hiv1coreceptortropismanddiseaseprogressioninchildrenandyoungadultswithperinatallyacquiredhiv1infectionthehiccupstudy |
_version_ |
1721479974194511872 |